Pune-based Emcure Pharmaceuticals listed at Rs 1,325, a 31.4% premium on Rs 1,008 IPO price. QIBs subscribed 195.8 times, non-institutional investors 48.3 times. Analysts recommend long-term holding. IPO proceeds target debt and corporate purposes. Offering products in therapeutic areas, Emcure recorded Rs 6,658 crore revenue in FY24 and operates in Europe, Canada.
